Pay in 4 interest-free payments of $5.02 Learn more
Ships within 48 hours Β· Estimated delivery Sep 2 - Sep 7
Do not automatically reach for a maximum strength dose
doi:10.1056/NEJMoa2511774
Galectin-3 and S100A9: Novel Diabetogenic Factors Mediating Pancreatic Cancer-Associated Diabetes
5.2 Acute Pancreatitis Acute pancreatitis, including fatal and non-fatal hemorrhagic or necrotizing pancreatitis, has been observed in patients treated with GLP-1 receptor agonists, including WEGOVY [see Adverse Reactions (6)]
The risk of gastrointestinal adverse events is increased with GLP-1RA therapy but these effects tend to be mild-to-moderate and transient, and are not the reason for observed weight loss
All these could pose significant financial burdens on the companies involved
US$ 23.79
US$ 27.40
US$ 29.91
US$ 22.64
US$ 22.78
US$ 22.52
US$ 26.55
